North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 0.910

+4.6%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (161)	12/1/1997 7:25:00 AM
From: Don W Stone	Read Replies (1) of 507

George: Very interesting. They are talking about the competition. " Whole cell pertussis vaccine vs. multicomponent acellular pertussis" These guys , who apparently were not working for the companies who's vaccines they were running trials on, found the efficacy of the whole cell vaccine to be SIMILAR, YES similar, to the 5 component and 3 component vaccines ,... and the 2 component had a LOWER efficacy. " wow! This was in the current , lastest issue of " The Lancet" Nov.27,'97. Their study, if nothing else, proves that you can't compare results of trial data across different clinical trials. I did a search and came up with a Dec. '96 issue that bombed the competition's combining of DTaP with Hib, for the same reasons that the FDA Advisory committee shot it down just a couple of months ago. A lowering of the immunocity of the Hib when combined. NVX will be the only one with a DTaP-Hib vaccine eventually. Thanks again, I hadn't gone there in a quite awhile. :-}

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next